You are here

Article Text

Article menu
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP
  1. Hans W Axelson1,
  2. Gunnar Öberg2,
  3. Håkan Askmark3
  1. 1
    Clinical Neurophysiology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden
  2. 2
    Haematology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden
  3. 3
    Neurology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden
  1. hans.axelson{at}akademiska.se

Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterised by the occurrence of symmetrical weakness and sensory impairment in arms and legs. The course is relapsing or chronic and progressing. CIDP is considered to be an autoimmune disease, which is supported by the beneficial response to immunomodulating therapies in most patients. We report on a patient with CIDP who has been in remission for more than 3 years after treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP on two occasions.

https://doi.org/10.1136/bcr.09.2008.0927

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.